The QMENTA Medical Imaging AI Analyses Catalog and Disease Biomarker Packages are a first-in-industry solution that aggregates and curates industry standard and proprietary AI tools. 

Boston, MA – November 30, 2021 – QMENTA announced today the launch of its Imaging AI Analyses Catalog, a world-leading comprehensive set of neurology-focused AI (Artificial Intelligence) imaging analysis tools that will advance the fight against brain diseases. 

The Imaging AI Analyses Catalog hosts over 50 proprietary and industry gold-standard algorithms that provide objective biomarker and brain structure measurement and disease progression tracking for use in clinical studies. The catalog allows algorithms to be searched by disease focus, biomarker type and regulatory clearance status.  In addition to this one-stop access to best-in-class algorithms, multiple point solutions are integrated and unified into disease-specific Biomarker Packages, initially launching for Alzheimer’s Disease, Multiple Sclerosis and Neuro-oncology, making the choice of optimal algorithms clear and simple. 

Recent years have seen the development of revolutionary AI tools and biomarker algorithms from leading research institutions and AI innovators around the globe. But access and use of these tools has been fragmented and complex, oftentimes built by engineers for engineers. Our goal is to make this game-changing technology easily accessible and embedded in the daily workflows of the experts. Our PhD level experts curate the catalog to ensure the highest levels of scientific validation,” commented Paulo Rodrigues, CTO and Co-Founder, QMENTA.

The comprehensive set of tools is accessible through QMENTA’s several Platform solutions providing a one-stop-shop to manage and reproducible quantify image-based outcome measures. QMENTA’s platform unique ability to apply and unify outcomes from multiple tools makes it the ideal partner to execute multi-factorial studies spanning clinical research, clinical trials or care delivery.

The coherent set of tools in the catalog currently includes 50 industry gold standard and proprietary AI biomarker neuroimaging analysis algorithms, with more cutting edge tools added o a regular basis. The solution also provides a Software Development Kit so that AI innovatorscan easily and rapidly port novel AI models to the catalog, greatly reducing the time to market for AI innovators, and immediately reach new markets in clinical research and clinical trials.

The disease biomarker packages provide a set of related tools that can be combined with each other for more in-depth and multi-factorial understanding of CNS diseases,” said QMENTA CEO Vesna Prchkovska, PhD. "The catalog enables brain experts to have a unified perspective on the brain and its diseases, instead of having to deal with several sparse single point solutions. Both the catalog and biomarker packages can easily be expanded to address other therapeutic and disease areas beyond neurology” she added. 


Key benefits of the AI Tools Catalog for the neurology field include: 


  • Most comprehensive and growing AI ecosystem for democratization and distribution of innovative AI tools
  • More cost-effective and simpler than purchasing multiple point solutions from diverse vendors, with a world-leading catalog on one single platform and a dedicated and expert support team.
  • Consolidated access to globally curated and scientifically verified Best-in-Class algorithms
  • Searchable by disease area, biomarker type and regulatory clearance
  • Confidence in algorithm performance and provenance with clear source referencing
  • All tools are easily executable directly on the QMENTA platform, allowing users to run and combine multiple AI Tools outputs simultaneously

Schedule a meeting with QMENTA experts at RSNA to learn more.